DHL Group, a global logistics provider, plans to invest EUR 2 billion ($2.24 billion) over the next five years to enhance its logistics capabilities in the life-sciences and healthcare sector. Fifty percent of the investment is allocated to the Americas, 25% to Asia Pacific, and 25% to the EMEA region (Europe, Middle East, and Africa).  

The investment will enhance infrastructure and technology across all logistics touchpoints – from storage, order fulfillment, and distribution to global shipping and last-mile delivery. A significant part of the investment will be allocated to establishing new cross-divisional GDP (Good Distribution Practices)-certified Pharma Hubs for multi-temperature shipments lanes, expanding cold-chain capacity in existing facilities, commissioning new temperature-controlled vehicles, and enhancing both passive and active packaging for sustainability.  

Currently, DHL operates nearly 600 sites, hubs, and warehouses across nearly 130 countries dedicated to life sciences and healthcare logistics, encompassing a total of more than 2.5 million square meters of temperature-controlled warehouse space The company’s life sciences and healthcare logistic business posted 2024 global revenues of approximately EUR 5 billion ($5.6 billion). The company estimates it will add an additional EUR 5 billion ($5.6 billion) in projected incremental revenue by 2030. 

Separately, late last month (March 2025), the company agreed to acquire CRYOPDP, a specialty courier providing logistics services for clinical trials, biopharmaceuticals, and cell & gene therapies, from Cyroport, a global supply-chain company for the life-sciences industry.  

DHL and Cyroport also announced a strategic partnership to strengthen their supply-chain service offerings for the global life sciences and healthcare sector. The acquisition and partnership are subject to regulatory approvals. 

Source: DHL ($2-Bn investment) and DHL (CRYOPDP)